Ocuphire Pharma (OCUP) News Today → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free OCUP Stock Alerts $1.54 +0.01 (+0.33%) (As of 05:13 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineOcuphire Pharma, Inc. (OCUP)finance.yahoo.com - April 24 at 6:16 PMOcuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meetingglobenewswire.com - April 22 at 8:00 AMOcuphire Pharma (NASDAQ:OCUP) Trading Down 4.3%americanbankingnews.com - April 16 at 1:52 AMFirst Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgeryglobenewswire.com - April 11 at 10:03 AMOcuphire Announces Commercial Launch Of Ryzumvi In U.S. By Its Partner Viatrismarkets.businessinsider.com - April 1 at 11:54 AMOcuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatrisglobenewswire.com - April 1 at 7:14 AMOcuphire Pharma COO acquires $4.1k in company stockinvesting.com - March 27 at 4:21 PMOcuphire Pharma, Inc. (NASDAQ:OCUP) CFO Nirav S. Jhaveri Buys 10,000 Sharesinsidertrades.com - March 26 at 5:00 AMOcuphire Pharma, Inc. (NASDAQ:OCUP) CEO George Magrath Buys 25,000 Sharesinsidertrades.com - March 21 at 10:32 AMOCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023investorplace.com - March 15 at 1:01 PMEarnings Update: Ocuphire Pharma, Inc. (NASDAQ:OCUP) Just Reported And Analysts Are Trimming Their Forecastsfinance.yahoo.com - March 13 at 8:02 AMBuy Rating Affirmed for Ocuphire Pharma on Promising APX3330 Progress for Diabetic Retinopathy Treatmentmarkets.businessinsider.com - March 11 at 1:39 PMOcuphire Pharma Full Year 2023 Earnings: Misses Expectationsfinance.yahoo.com - March 10 at 2:37 PMOcuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Updateglobenewswire.com - March 8 at 8:00 AMOcuphire (OCUP) to Report Q4 Earnings: What's in the Cards?msn.com - March 4 at 9:52 AM7 Under-the-Radar Biotech Stocks Gearing Up for Liftoffinvestorplace.com - February 26 at 3:20 PMOcuphire Pharma to Present in the BIO CEO & Investor Conferenceglobenewswire.com - February 23 at 8:00 AMOcuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - February 15 at 4:10 PMOcuphire Pharma Inc (OCUP)uk.investing.com - February 15 at 12:57 PMOcuphire Pharma Strengthens Leadership Team with Key Appointmentsfinance.yahoo.com - February 14 at 10:49 AMOcuphire Pharma Strengthens Leadership Team with Key Appointmentsglobenewswire.com - February 14 at 8:00 AMOcuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conferencefinance.yahoo.com - February 5 at 8:30 AMOcuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)finance.yahoo.com - January 24 at 5:10 PMOcuphire Pharma files for a $175M mixed securities shelfmsn.com - January 10 at 5:36 PMOcuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditionsfinance.yahoo.com - January 4 at 10:08 AMBuy Rating Affirmed for Ocuphire Pharma on Promising Clinical Advancements and Strategic Partnershipsmarkets.businessinsider.com - November 30 at 12:56 PMBears are Losing Control Over Ocuphire Pharma, Inc. (OCUP), Here's Why It's a 'Buy' Nowmsn.com - November 30 at 12:56 PMOcuphire announces appointment of Joseph Schachle as chief operating officermsn.com - November 27 at 10:16 AMOcuphire Pharma Names Joseph Schachle COOmarkets.businessinsider.com - November 27 at 10:16 AMOcuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officerfinance.yahoo.com - November 27 at 10:16 AMOcuphire Pharma Stock (NASDAQ:OCUP) Earnings Dates and Earning Callsbenzinga.com - November 15 at 3:37 PMRecap: Ocuphire Pharma Q3 Earningsbenzinga.com - November 13 at 4:24 PMOcuphire Pharma GAAP EPS of $0.25, revenue of $11.94Mmsn.com - November 13 at 4:24 PMOcuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Updatefinance.yahoo.com - November 13 at 8:37 AMDeclining Stock and Solid Fundamentals: Is The Market Wrong About Ocuphire Pharma, Inc. (NASDAQ:OCUP)?finance.yahoo.com - November 10 at 12:12 PMPromising FDA Feedback and Potential Market Opportunities Drive Buy Rating for Ocuphire Pharmamarkets.businessinsider.com - November 4 at 9:43 AMOcuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathyfinance.yahoo.com - November 2 at 9:26 AMOcuphire Pharma appoints George Magrath as CEOmsn.com - November 1 at 8:59 AMOcuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Directorfinance.yahoo.com - November 1 at 8:59 AMOcuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcasefinance.yahoo.com - October 26 at 8:53 AMOcuphire Pharma to Present at Euretina and Retina Society Conferences in Octoberfinance.yahoo.com - October 6 at 8:27 AMAnalysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Ocuphire Pharma (OCUP)markets.businessinsider.com - September 28 at 5:01 PMViatris and Ocuphire Pharma get FDA green light for eye treatmentmsn.com - September 28 at 7:00 AMOcuphire Shares Rally Premarket as FDA Approves Ryzumvi Eye Dropsmarketwatch.com - September 28 at 1:54 AMBuy Rating for Ocuphire Pharma: FDA Approval of Ryzumvi and Anticipated Developments Boost Stock’s Valuemarkets.businessinsider.com - September 28 at 1:54 AMOcuphire Pharma to Participate in Three Upcoming Investment Bank Conferencesfinance.yahoo.com - September 11 at 9:56 AMBiotech Stocks Facing FDA Decision In September 2023markets.businessinsider.com - August 31 at 6:23 PMAbstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposiumfinance.yahoo.com - August 28 at 10:21 AMH.C. Wainwright Keeps Their Buy Rating on Ocuphire Pharma (OCUP)markets.businessinsider.com - August 15 at 9:17 AMCantor Fitzgerald Reiterates Ocuphire Pharma (OCUP) Overweight Recommendationmsn.com - August 14 at 6:15 PM Get Ocuphire Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUP and its competitors with MarketBeat's FREE daily newsletter. Email Address Mysterious Gold Leverage Just Announced (Ad)World's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers. Find out what it is and see how you can get in with just a few dollars. OCUP Media Mentions By Week OCUP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCUP News Sentiment▼0.000.41▲Average Medical News Sentiment OCUP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCUP Articles This Week▼21▲OCUP Articles Average Week Get Ocuphire Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Rockwell Medical News Bolt Biotherapeutics News Aadi Bioscience News Xilio Therapeutics News NRx Pharmaceuticals News NextCure News Clene News CalciMedica News Eledon Pharmaceuticals News Marker Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCUP) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeThe World's First "$20 Trillion Drug?"Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocuphire Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
